You are here

Article info

Article menu
Basic tumor immunology
Original research
Venetoclax improves CD20 immunotherapy in a mouse model of MYC/BCL2 double-expressor diffuse large B-cell lymphoma

Authors

  • Javier Melchor Department of Biochemistry and Genetics, Universidad de Navarra, Pamplona, SpainHemato-Oncology Program, Center for Applied Medical Research (CIMA), Pamplona, Spain PubMed articlesGoogle scholar articles
  • Marcos Garcia-Lacarte Department of Biochemistry and Genetics, Universidad de Navarra, Pamplona, SpainHemato-Oncology Program, Center for Applied Medical Research (CIMA), Pamplona, SpainNavarra Institute for Health Research (IdiSNA), Pamplona, Spain PubMed articlesGoogle scholar articles
  • Sara C. Grijalba Department of Biochemistry and Genetics, Universidad de Navarra, Pamplona, SpainNavarra Institute for Health Research (IdiSNA), Pamplona, Spain PubMed articlesGoogle scholar articles
  • Adrián Arnaiz-Leché Department of Biochemistry and Genetics, Universidad de Navarra, Pamplona, SpainNavarra Institute for Health Research (IdiSNA), Pamplona, Spain PubMed articlesGoogle scholar articles
  • Marién Pascual Hemato-Oncology Program, Center for Applied Medical Research (CIMA), Pamplona, Spain PubMed articlesGoogle scholar articles
  • Carlos Panizo Navarra Institute for Health Research (IdiSNA), Pamplona, SpainDepartment of Hematology, Clinica Universidad de Navarra, Pamplona, SpainCurrent address: Department of Hematology and Hemotherapy, Hospital Universitario Donostia, San Sebastián, Spain PubMed articlesGoogle scholar articles
  • Oscar Blanco Department of Pathology, Universidad de Salamanca, Salamanca, Spain PubMed articlesGoogle scholar articles
  • Victor Segura Bio-informatic Unit, Center for Applied Medical Research (CIMA), Pamplona, SpainCurrent address: Data Intelligence Unit, Techedge Spain, Madrid, Spain PubMed articlesGoogle scholar articles
  • Francisco J. Novo Department of Biochemistry and Genetics, Universidad de Navarra, Pamplona, SpainNavarra Institute for Health Research (IdiSNA), Pamplona, Spain PubMed articlesGoogle scholar articles
  • Juan Garcia Valero Department of Hematology-Oncology, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, SpainCentro de Investigación Biomédica en Red de Cáncer (CIBERONC), Instituto de Salud Carlos III, Madrid, Spain PubMed articlesGoogle scholar articles
  • Patricia Pérez-Galán Department of Hematology-Oncology, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, SpainCentro de Investigación Biomédica en Red de Cáncer (CIBERONC), Instituto de Salud Carlos III, Madrid, Spain PubMed articlesGoogle scholar articles
  • Jose A. Martinez-Climent Hemato-Oncology Program, Center for Applied Medical Research (CIMA), Pamplona, SpainNavarra Institute for Health Research (IdiSNA), Pamplona, SpainCentro de Investigación Biomédica en Red de Cáncer (CIBERONC), Instituto de Salud Carlos III, Madrid, Spain PubMed articlesGoogle scholar articles
  • Sergio Roa Department of Biochemistry and Genetics, Universidad de Navarra, Pamplona, SpainHemato-Oncology Program, Center for Applied Medical Research (CIMA), Pamplona, SpainNavarra Institute for Health Research (IdiSNA), Pamplona, SpainCentro de Investigación Biomédica en Red de Cáncer (CIBERONC), Instituto de Salud Carlos III, Madrid, Spain PubMed articlesGoogle scholar articles

Citation

Melchor J, Garcia-Lacarte M, Grijalba SC, et al
Venetoclax improves CD20 immunotherapy in a mouse model of MYC/BCL2 double-expressor diffuse large B-cell lymphoma
Journal for ImmunoTherapy of Cancer 2023;11:e006113. doi: 10.1136/jitc-2022-006113
Online issue publication 
October 18, 2023

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.